ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Oddvar Moen
Erik Fosse
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moen, O.
Right arrow Articles by Venge, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moen, O.
Right arrow Articles by Venge, P.

Ann Thorac Surg 1995;60:1317-1323
© 1995 The Society of Thoracic Surgeons

Original Articles: Cardiovascular

Disparity in Blood Activation by Two Different Heparin-Coated Cardiopulmonary Bypass Systems

Oddvar Moen, MD, Erik Fosse, MD, PhD, Vibeke Brockmeier, MD, Conny Andersson, CCP, Tom Eirik Mollnes, MD, PhD, Kolbjørn Høgåsen, MD, Per Venge, MD, PhD

Departments of Surgery and Anesthesiology, Institute for Experimental Research, Ullevaal Hospital, Oslo, Norway

Accepted for publication July 5, 1995.

Background. Several studies have indicated reduced ``blood activation'' in heparin-coated cardiopulmonary bypass systems. The present study compares the effect of two different heparin coatings on different blood activation indices.

Methods. Low-risk patients (n = 40) were randomized to coronary artery bypass grafting using cardiopulmonary bypass with surfaces coated entirely by either the Duraflo II heparin coat or the Carmeda Biological Active Surface, or with identical uncoated equipment. In all cases, a standard systemic heparin dosage was used. Complement activation (C3 activation products C3bc and C3a and formation of fluid phase terminal SC5b-9 complement complex), neutrophil activation (lactoferrin and myeloperoxidase), and lytic inhibitors (vitronectin and clusterin) were quantified during cardiopulmonary bypass and 6 hours postoperatively.

Results. Heparin coating by either method reduced the formation of terminal SC5b-9 complement complex and the release of lactoferrin and myeloperoxidase compared with uncoated systems. Lactoferrin and myeloperoxidase levels increased significantly during cardiopulmonary bypass in the Duraflo II group, whereas no significant increase was observed in the Carmeda Biological Active Surface group. The least formation of terminal SC5b-9 complement complex and neutrophil activation was observed with the Maxima Carmeda Biological Active Surface–coated equipment. The vitronectin and clusterin concentrations were significantly less reduced in the Duraflo II compared with the control group. This study underlines the importance of terminal SC5b-9 complement complex as a suitable marker in the evaluation of complement activation during cardiopulmonary bypass.

Conclusions. Both heparin coatings reduce blood activation, probably more so with Carmeda Biological Active Surface than with Duraflo II.




This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou
Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes
Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al.
Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline
Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. E. Jessen
Pro: Heparin-Coated Circuits Should be Used for Cardiopulmonary Bypass
Anesth. Analg., December 1, 2006; 103(6): 1365 - 1369.
[Full Text] [PDF]

Home page
 PerfusionHome page
H. I Flom-Halvorsen, E Ovrum, F Brosstad, G Tangen, M A. Ringdal, and R Oystese
Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction
Perfusion, September 1, 2002; 17(5): 339 - 345.
[Abstract] [PDF]

Home page
 PerfusionHome page
J A Murphy, C M Savage, S K Alpard, D J Deyo, J B Jayroe, and J B Zwischenberger
Low-dose versus high-dose heparinization during arteriovenous carbon dioxide removal
Perfusion, December 1, 2001; 16(6): 460 - 468.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
E. Ovrum, G. Tangen, R. Oystese, M. A. L. Ringdal, and R. Istad
Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations
J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0324 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
S. Svenmarker, E. Sandstrom, T. Karlsson, S. Haggmark, E. Jansson, M. Appelblad, R. Lindholm, and T. Aberg
Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits
Eur. J. Cardiothorac. Surg., January 1, 2001; 19(1): 47 - 53.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
H. P. Wendel and G. Ziemer
Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation
Eur. J. Cardiothorac. Surg., September 1, 1999; 16(3): 342 - 350.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
S. T Baksaas, V. Videm, E. Fosse, H. Karlsen, T. Pedersen, T. E Mollnes, T. A Hagve, and J. L Svennevig
In vitro evaluation of new surface coatings for extracorporeal circulation
Perfusion, January 1, 1999; 14(1): 11 - 19.
[Abstract] [PDF]

Home page
 PerfusionHome page
C. Baufreton, M. Moczar, L. Intrator, P. G. Jansen, H. te Velthuis, P. Le Besnerais, J. P. Farcet, C. R. Wildevuur, and D. Y Loisance
Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits
Perfusion, December 1, 1998; 13(6): 419 - 427.
[Abstract] [PDF]

Home page
 PerfusionHome page
C B. Mahoney
Heparin-bonded circuits: clinical outcomes and costs
Perfusion, May 1, 1998; 13(3): 192 - 204.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. Lundblad, O. Moen, and E. Fosse
Endothelin-1 and Neutrophil Activation During Heparin-Coated Cardiopulmonary Bypass
Ann. Thorac. Surg., May 1, 1997; 63(5): 1361 - 1367.
[Abstract] [Full Text]

Home page
 PerfusionHome page
H E Hogevold, O Moen, E Fosse, P Venge, J Braten, C Andersson, and T Lyberg
Effects of heparin coating on the expression of CD11b, CD11c and CD62L by leucocytes in extracorporeal circulation in vitro
Perfusion, January 1, 1997; 12(1): 9 - 20.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
O. Moen, K. Hogasen, E. Fosse, E. Dregelid, V. Brockmeier, P. Venge, M. Harboe, and T. E. Mollnes
Attenuation of Changes in Leukocyte Surface Markers and Complement Activation With Heparin-Coated Cardiopulmonary Bypass
Ann. Thorac. Surg., January 1, 1997; 63(1): 105 - 111.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1995 by The Society of Thoracic Surgeons.